Shree Ganesh Bio (539470)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• P/B of 0.72 gives a 28% discount to stated book value of ₹1.66 per share.
• Latest quarter is near breakeven with ₹1 Cr sales and ₹0 Cr net profit, showing no immediate cash burn.
• ROCE is positive at 0.62% even though ROE is negative, suggesting some asset productivity remains.

Concerns

• Sales growth of -95.14% indicates the core business has nearly collapsed.
• ROE of -0.45%, P/E of 0.00, and profit growth of -58.44% show no dependable earnings power.
• Piotroski F-Score of 3/9 points to weak balance-sheet and operating fundamentals.
• No dividend and promoter holding disclosed as N/A reduce investor confidence.

AI Analysis

When I look at Shree Ganesh Bio, I see a business that has almost ceased to be a business. Sales are down 95.14%, and the latest quarter generated only ₹1 crore of revenue with zero net profit. At a market capitalisation of ₹48 crore, the market is paying about 48 times that quarterly run-rate for an operation whose economics are barely visible. The P/E of 0.00 is meaningless because there are no meaningful earnings. Profit growth is down 58.44%. This is not a growth story. Benjamin Graham taught me to buy with a margin of safety. Here the price-to-book is 0.72, so on paper I get ₹1.66 of book value for ₹1.20. That sounds like an asset play. But I must ask: is the book value real? ROE is -0.45%, so equity is earning nothing. ROCE of 0.62% only says capital employed is just above break-even. A Piotroski score of 3 out of 9 reinforces my worry about weak financial health. There is no dividend, promoter holding is undisclosed, and there is no clear source of future revenue. A 95% sales collapse is not a cyclical dip; it is an evaporation of business. I prefer wonderful companies at fair prices to broken companies at cheap-looking prices. The stock sits at the top of its 52-week range, ₹1.20, but the fundamentals do not support optimism. Unless management can show a credible path back to profitability and prove that book value is worth more than paper, this is a speculative vehicle, not an investment. Benjamin Graham said price is what you pay, value is what you get. Today, I struggle to see the value. I would wait for evidence, no matter how tempting the low price looks.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer